Actuate Therapeutics (NASDAQ:ACTU) Stock Price Down 5.4% – What’s Next?

Shares of Actuate Therapeutics (NASDAQ:ACTU) fell 5.4% on Wednesday . The company traded as low as $8.44 and last traded at $8.79. 13,214 shares changed hands during trading, a decline of 68% from the average session volume of 41,467 shares. The stock had previously closed at $9.29.

Actuate Therapeutics Price Performance

The business’s 50-day simple moving average is $8.46.

Institutional Investors Weigh In On Actuate Therapeutics

A hedge fund recently bought a new stake in Actuate Therapeutics stock. KG&L Capital Management LLC bought a new stake in Actuate Therapeutics (NASDAQ:ACTU) during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 12,000 shares of the company’s stock, valued at approximately $89,000. KG&L Capital Management LLC owned 0.06% of Actuate Therapeutics as of its most recent filing with the Securities & Exchange Commission.

About Actuate Therapeutics

Actuate Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of cancers. The company’s lead product candidate is Elraglusib Injection, a novel glycogen synthase kinase-3 inhibitor to treat metastatic pancreatic ductal adenocarcinoma. It also develops Elraglusib for the treatment of Ewing sarcoma, metastatic melanoma, and colorectal cancer.